Site icon News 365

U.S. Health Secretary Kennedy Cancels Major mRNA Vaccine Contracts

Health and Human Services Secretary Robert F. Kennedy Jr. speaks as President Donald Trump listens at an event to promote his proposal to improve Americans' access to their medical records in the East Room of the White House, Wednesday, July 30, 2025, in Washington. (AP Photo/Mark Schiefelbein)

Kennedy Cancels Nearly $500 Million in mRNA Vaccine Contracts

U.S. Health Secretary Robert F. Kennedy Jr. has announced the termination of approximately $500 million in federal contracts for mRNA vaccine development. This move affects 22 projects, many led by major firms like Moderna, Pfizer, and Sanofi Pasteur, focusing on vaccines for respiratory illnesses such as COVID-19, seasonal flu, and H5N1 bird flu. Reddit+14Politico+14The Times+14Tribune Online+15Fierce Biotech+15SSBCrack News+15


🚫 Policy Shift Toward Non‑mRNA Platforms

In a statement, Kennedy argued that mRNA vaccines do not provide effective protection against upper respiratory viruses and may encourage viral mutations that prolong pandemics. He stated the funding will be redirected toward “safer, broader vaccine platforms” such as whole-virus vaccines and novel immunizations. SSBCrack News+7Tribune Online+7Deutsche Welle+7


Critics Sound Alarm on Public Health Risk

Experts and former officials have strongly condemned the decision:


Broader Anti‑Vaccine Shake‑Up

Kennedy’s actions are part of a larger overhaul of U.S. vaccine policy. Since taking office, he has:


What Happens Next?

Kennedy Cancels Nearly $500 Million in mRNA Vaccine Contracts

U.S. Health Secretary Robert F. Kennedy Jr. has announced the termination of approximately $500 million in federal contracts for mRNA vaccine development. The move affects 22 projects, including initiatives led by Moderna, Pfizer, and Sanofi Pasteur, many of which targeted respiratory illnesses such as COVID‑19, seasonal flu, and H5N1 bird flu.


🚫 Policy Shift Toward Non‑mRNA Platforms

In his announcement, Kennedy argued that mRNA vaccines do not provide effective protection against upper respiratory viruses and may encourage viral mutations that prolong pandemics. He said funding will instead be redirected toward “safer, broader vaccine platforms,” such as whole‑virus vaccines and novel immunization approaches.


Critics Warn of Public Health Risks

The decision has drawn sharp criticism from public health leaders and former officials.

Critics warn the cuts could leave the U.S. more vulnerable to future outbreaks and slow the pace of vaccine innovation.


Broader Anti‑Vaccine Policy Shift

The cancellations are part of a sweeping overhaul of U.S. vaccine policy under Kennedy’s leadership. Since taking office, he has:


What Happens Next

While some contracts close to completion may proceed, no new mRNA vaccine projects will be initiated. Kennedy has pledged to invest the redirected funds in alternative vaccine technologies, but details remain unclear.

Industry analysts warn the decision could deter pharmaceutical investment in the U.S. and weaken the nation’s ability to respond to rapidly evolving pathogens.

As the debate intensifies, the policy marks one of the most significant reversals in U.S. vaccine strategy in decades — with implications that could shape the country’s pandemic readiness for years to come.

Share this content:

Exit mobile version